Drug hypersensitivity reactions in skin: Understanding mechanisms and the development of diagnostic and predictive tests

Toxicology

Volumn 194, Issue 3, 2004, Pages 179-196

  Naisbitt, Dean J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Drug hypersensitivity; Drug metabolism; Skin; T cells

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; ABACAVIR; AMOXICILLIN; ANTICONVULSIVE AGENT; CARBAMAZEPINE; COTRIMOXAZOLE; CYTOKINE; DRUG METABOLITE; EOTAXIN; GAMMA INTERFERON; HYDRALAZINE; HYDROXYLAMINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; ISONIAZID; LAMOTRIGINE; LYMPHOCYTE ANTIGEN; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENINDIONE; PHENOBARBITAL; PHENYTOIN; PROCAINAMIDE; SULFAMETHOXAZOLE; SULFONAMIDE; TRIMETHOPRIM; UNINDEXED DRUG;

ANTICONVULSANT ACTIVITY; ANTIGEN PRESENTATION; BULLOUS SKIN DISEASE; CELL CULTURE; COVALENT BOND; CYTOTOXICITY; DIAGNOSTIC TEST; DRUG ACTIVATION; DRUG ACTIVITY; DRUG ANTIGENICITY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; EOSINOPHILIA; FEVER; HEPATITIS; HUMAN; HYPERSENSITIVITY REACTION; IMMUNE RESPONSE; MACULOPAPULAR RASH; NEPHRITIS; NONHUMAN; PAPULAR SKIN DISEASE; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BINDING; PUSTULE; RASH; REVIEW; SKIN ALLERGY; SKIN DISEASE; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0348110315     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2003.09.004     Document Type: Review

References (105)

1. Bessmertny O., Pham T. Antiepileptic hypersensitivity syndrome: clinicians beware and be aware. Curr. Allergy Asthma Rep. 2:2002;34-39.
2. Blanca M., Posadas S., Torres M.J., Leyva L., Mayorga C., Gonzalez L., Juarez C., Fernandez J., Santamaria L.F. Expression of the skin-homing receptor in peripheral blood lymphocytes from subjects with nonimmediate cutaneous allergic drug reactions. Allergy. 55:2000;998-1004.
3. Bocquet H., Bagot M., Roujeau J.C. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin. Cutan. Med. Surg. 15:1996;250-257.
4. Britschgi M., Steiner U.C., Schmid S., Depta J.P., Senti G., Bircher A., Burkhart C., Yawalkar N., Pichler W.J. T-cell involvement in drug-induced acute generalised exanthematous pustulosis. J. Clin. Invest. 107:2001;1433-1441.
5. Brugnolo F., Annunziato F., Sampognaro S., Campi P., Manfredi M., Matucci A., Blanca M., Romagnani S., Maggi E., Parronchi P. Highly Th2-skewed cytokine profile of beta-lactam-specific T cells from nonatopic subjects with adverse drug reactions. J. Immunol. 163:1999;1053-1059.
6. Buhl R., Holroyd K.J., Mastrangeli A., Cantin A.M., Jaffe H.A., Wells F.B., Saltini C., Crystal R.G. Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet. 2:1989;1294-1298.
7. Burkhart C., von Greyerz S., Depta J.P., Naisbitt D.J., Britschgi M., Park K.B., Pichler W.J. Influence of reduced glutathione on the proliferative response of sulfamethoxazole-specific and sulfamethoxazole-metabolite-specific human CD4+ T-cells. Br. J. Pharmacol. 132:2001;623-630.
8. Burkhart C., Britschgi M., Strasser I., Depta J.P., von Greyerz S., Barnaba V., Pichler W.J. Non-covalent presentation of sulfamethoxazole to human CD4+ T cells is independent of distinct human leucocyte antigen-bound peptides. Clin. Exp. Allergy. 32:2002;1635-1643.
9. Claesen M., Moustafa M.A., Adline J., Vandervorst D., Poupaert J.H. Evidence for an arene oxide-NIH shift pathway in the metabolic conversion of phenytoin to 5-(4-hydroxyphenyl)-5-phenylhydantoin in the rat and in man. Drug Metab. Dispos. 10:1982;667-671.
10. Cribb A.E., Miller M., Tesoro A., Spielberg S.P. Peroxidase-dependent oxidation of sulfonamides by monocytes and neutrophils from humans and dogs. Mol. Pharmacol. 38:1990;744-751.
11. Cribb A.E., Spielberg S.P., Griffin G.P. N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab. Dispos. 23:1995;406-414.
12. Dearman R.J., Moussavi A., Kemeny D.M., Kimber I. Contribution of CD4+ and CD8+ T lymphocyte subsets to the cytokine secretion patterns induced in mice during sensitization to contact and respiratory chemical allergens. Immunology. 89:1996;502-510.
13. Dearman R.J., Warbrick E.V., Humphreys I.R., Kimber I. Characterisation in mice of the immunological properties of five allergenic acid anhydrides. J. Appl. Toxicol. 20:2000;221-230.
14. Dearman R.J., Warbrick E.V., Skinner R., Kimber I. Cytokine fingerprinting of chemical allergens: species comparisons and statistical analyses. Food Chem. Toxicol. 40:2002;1881-1892.
15. Dearman R.J., Betts C.J., Humphreys N., Flanagan B.F., Gilmour N.J., Basketter D.A., Kimber I. Chemical allergy: considerations for the practical application of cytokine profiling. Toxicol. Sci. 71:2003;137-145.
16. Dorner B.G., Scheffold A., Rolph M.S., Huser M.B., Kaufmann S.H., Radbruch A., Flesch I.E., Kroczek R.A. MIP-1alpha, MIP-1beta, RANTES, and ATAC/lymphotactin function together with IFN-gamma as type 1 cytokines. Proc. Natl. Acad. Sci. U.S.A. 99:2002;6181-6186.
17. Eadie M.J. Formation of active metabolites of anticonvulsant drugs. A review of their pharmacokinetic and therapeutic significance. Clin. Pharmacokinet. 21:1991;27-41.
18. Eck H.P., Gmunder H., Hartmann M., Petzoldt D., Daniel V., Droge W. Low concentrations of acid-soluble thiol (cysteine) in the blood plasma of HIV-1-infected patients. Biol. Chem. Hoppe Seyler. 370:1989;101-108.
19. Ellis M.K., Hill S., Foster P.M. Reactions of nitrosonitrobenzenes with biological thiols: identification and reactivity of glutathion-S-yl conjugates. Chem. Biol. Interact. 82:1992;151-163.
20. Engler, O., Strasser, I., Naisbitt, D.J., Cerny, A., Pichler, W.J. A chemically inert drug can stimulate T-cells in vitro by their T-cell receptor and induce cytokine secretion, proliferation and cytotoxicity, submitted for publication.
21. Farrell J., Naisbitt D.J., Drummond N.S., Depta J.P., Vilar F.J., Pirmohamed M., Park B.K. Characterisation of sulfamethoxazole and sulfamethoxazole metabolite-specific T-cell responses in animals and man. J. Pharmacol. Exp. Ther. 306:2003;229-237.
22. Friedmann P.S., Strickland I., Pirmohamed M., Park B.K. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch. Dermatol. 130:1994;598-604.
23. Gallucci S., Lolkema M., Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5:1999;1249-1255.
24. Gill H.J., Hough S.J., Naisbitt D.J., Maggs J.L., Kitteringham N.R., Pirmohamed M., Park B.K. The relationship between the disposition and immunogenicity of sulfamethoxazole in the rat. J. Pharmacol. Exp. Ther. 282:1997;795-801.
25. Gorbachev A.V., Fairchild R.L. Induction and regulation of T-cell priming for contact hypersensitivity. Crit. Rev. Immunol. 21:2001;451-472.
26. Hadden J.W. T-cell adjuvants. Int. J. Immunopharmacol. 16:1994;703-710.
27. Hari Y., Frutig-Schnyder K., Hurni M., Yawalkar N., Zanni M.P., Schnyder B., Kappeler A., von Greyerz S., Braathen L.R., Pichler W.J. T cell involvement in cutaneous drug eruptions. Clin. Exp. Allergy. 31:2001;1398-1408.
28. Hashizume H., Takigawa M., Tokura Y. Characterisation of drug-specific T cells in phenobarbital-induced eruption. J. Immunol. 168:2002;5359-5368.
29. Hertl M., Jugert F., Merk H.F. CD8+ dermal T cells from a sulphamethoxazole-induced bullous exanthem proliferate in response to drug-modified liver microsomes. Br. J. Dermatol. 132:1995;215-220.
30. Hofstra A.H., Li-Muller S.M., Uetrecht J.P. Metabolism of isoniazid by activated leukocytes. Possible role in drug-induced lupus. Drug Metab. Dispos. 20:1992;205-210.
31. Homey B., Alenius H., Muller A., Soto H., Bowman E.P., Yuan W., McEvoy L., Lauerma A.I., Assmann T., Bunemann E., Lehto M., Wolff H., Yen D., Marxhausen H., To W., Sedgwick J., Ruzicka T., Lehmann P., Zlotnik A. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat. Med. 8:2002;157-165.
32. Hopkins J.E., Naisbitt D.J., Humphreys N., Dearman R.J., Kimber I., Park B.K. Exposure of mice to sulfamethoxazole metabolite stimulates IL-5 expression. Toxicology. 178:2002;41.
33. Hopkins J.E., Naisbitt D.J., Dearman R.J., Kimber I., Park B.K. Distribution of antigen formation: a determinant of the nature of a cellular immune response to simple chemicals. Br. J. Clin. Pharmacol. 55:2003;444.
34. Hyson C., Sadler M. Cross sensitivity of skin rashes with antiepileptic drugs. Can. J. Neurol. Sci. 24:1997;245-249.
35. Irvine D.J., Purbhoo M.A., Krogsgaard M., Davis M.M. Direct observation of ligand recognition by T cells. Nature. 419:2002;845-849.
36. Janmohamed A., Dolphin C.T., Phillips I.R., Shephard E.A. Quantification and cellular localization of expression in human skin of genes encoding flavin-containing monooxygenases and cytochromes P450. Biochem. Pharmacol. 62:2001;777-786.
37. Ju C., Uetrecht J.P. Detection of 2-hydroxyiminostilbene in the urine of patients taking carbamazepine and its oxidation to a reactive iminoquinone intermediate. J. Pharmacol. Exp. Ther. 288:1999;51-56.
38. Kahn H.D., Faguet G.B., Agee J.F., Middleton H.M. 3rd Drug-induced liver injury. In vitro demonstration of hypersensitivity to both phenytoin and phenobarbital. Arch. Intern. Med. 144:1984;1677-1679.
39. Kakinuma T., Wakugawa M., Nakamura K., Hino H., Matsushima K., Tamaki K. High level of thymus and activation-regulated chemokine in blister fluid and sera of patients with bullous pemphigoid. Br. J. Dermatol. 148:2003;203-210.
40. Kalish R.S. Antigen processing: the gateway to the immune response. Am. Acad. Dermatol. 32:1995;640-652.
41. Kalish R.S., Askenase P.W. Molecular mechanisms of CD8+ T cell-mediated delayed hypersensitivity: implications for allergies, asthma, and autoimmunity. J. Allergy Clin. Immunol. 103:1999;192-199.
42. Kenna J.G., Satoh H., Christ D.D., Pohl L.R. Metabolic basis for a drug hypersensitivity: antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane. J. Pharmacol. Exp. Ther. 245:1988;1103-1109.
43. Kimber I., Basketter D.A., Gerberick G.F., Dearman R.J. Allergic contact dermatitis. Int. Immunopharmacol. 2:2002;201-211.
44. Lai W.G., Zahid N., Uetrecht J.P. Metabolism of trimethoprim to a reactive iminoquinone methide by activated human neutrophils and hepatic microsomes. J. Pharmacol. Exp. Ther. 291:1999;292-299.
45. Landsteiner K., Jacobs J. Studies on the sensitization of animals with simple chemical compounds. J. Exp. Med. 61:1935;643-656.
46. Leeder J.S. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia. 39:1998;S8-S16.
47. Leyva L., Torres M.J., Posadas S., Blanca M., Besso G., O'Valle F., del Moral R.G., Santamaria L.F., Juarez C. Anticonvulsant-induced toxic epidermal necrolysis: monitoring the immunologic response. J. Allergy Clin. Immunol. 105:2000;157-165.
48. Madden S., Maggs J.L., Park B.K. Bioactivation of carbamazepine in the rat in-vivo - evidence for the formation of reactive arene oxide(s). Drug Metab. Dispos. 24:1996;469-479.
49. Maggs J.L., Naisbitt D.J., Tettey J.N., Pirmohamed M., Park B.K. Metabolism of lamotrigine to a reactive arene oxide intermediate. Chem. Res. Toxicol. 13:2000;1075-1081.
50. Manchanda T., Hess D., Dale L., Ferguson S.G., Rieder M.J. Haptenation of sulfonamide reactive metabolites to cellular proteins. Mol. Pharmacol. 62:2002;1011-1026.
51. Masters P.A., O'Bryan T.A., Zurlo J., Miller D.Q., Joshi N. Trimethoprim-sulfamethoxazole revisited. Arch Intern. Med. 163:2003;402-410.
52. Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12:1994;991-1045.
53. Mauri-Hellweg D., Bettens F., Mauri D., Brander C., Hunziker T., Pichler W.J. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J. Immunol. 155:1995;462-472.
54. McFadden J.P., Basketter D.A. Contact allergy, irritancy and 'danger'. Contact Dermatitis. 42:2000;123-127.
55. Munns A.J., De Voss J.J., Hooper W.D., Dickinson R.G., Gillam E.M. Bioactivation of phenytoin by human cytochrome P450: characterisation of the mechanism and targets of covalent adduct formation. Chem. Res. Toxicol. 10:1997;1049-1058.
56. Naisbitt D.J., O'Neill P.M., Pirmohamed M., Park B.K. Synthesis and reactions of nitroso sulfamethoxazole with biological nucleophiles - implications for immune-mediated toxicity. Bioorg. Med. Chem. Let. 6:1996;1511-1516.
57. Naisbitt D.J., Hough S.J., Gill H.J., Pirmohamed M., Kitteringham N.R., Park B.K. Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity. Br. J. Pharmacol. 126:1999;1393-1407.
58. Naisbitt D.J., Gordon S.F., Pirmohamed M., Park B.K. Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf. 23:2000a;483-507.
59. Naisbitt D.J., Vilar F.J., Stalford A.C., Wilkins E.G., Pirmohamed M., Park B.K. Plasma cysteine deficiency and decreased reduction of nitrososulfamethoxazole with HIV infection. AIDS Res. Hum. Retroviruses. 16:2000b;1929-1938.
60. Naisbitt D.J., Williams D.P., Pirmohamed M., Kitteringham N.R., Park B.K. Reactive metabolites and their role in drug reactions. Curr. Opin. Allergy Clin. Immunol. 1:2001a;317-325.
61. Naisbitt D.J., Gordon S.F., Pirmohamed M., Burkhart C., Cribb A.E., Pichler W.J., Park B.K. Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. Br. J. Pharmacol. 133:2001b;295-305.
62. Naisbitt D.J., Farrell J., Gordon S.F., Maggs J.L., Burkhart C., Pichler W.J., Pirmohamed M., Park B.K. Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Mol. Pharmacol. 62:2002;628-637.
63. Naisbitt D.J., Pirmohamed M., Park B.K. Immunopharmacology of hypersensitivity reactions to drugs. Curr. Allergy Asthma Rep. 3:2003a;22-29.
64. Naisbitt D.J., Britschgi M., Wong G., Farrell J., Depta J.P., Chadwick D.W., Pichler W.J., Pirmohamed M., Park B.K. Hypersensitivity reactions to carbamazepine: characterisation of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol. Pharmacol. 63:2003b;732-741.
65. Naisbitt D.J., Farrell J., Wong G., Depta J.P.H., Dodd C.C., Hopkins J.E., Gibney C.A., Chadwick D.W., Pichler W.J., Pirmohamed M., Park B.K. Characterisation of drug-specific T-cells in lamotrigine hypersensitivity. J. Allergy Clin. Immunol. 111:2003c;1393-1403.
66. Nassif A., Bensussan A., Dorothee G., Mami-Chouaib F., Bachot N., Bagot M., Boumsell L., Roujeau J.C. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J. Invest. Dermatol. 118:2002;728-733.
67. Neuman M.G., Malkiewicz I.M., Shear N.H. A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes. Clin. Biochem. 33:2000;517-524.
68. Ohkuma Y., Kawanishi S. Oxidative DNA damage by a metabolite of carcinogenic and reproductive toxic nitrobenzene in the presence of NADH and Cu(II). Biochem. Biophys. Res. Commun. 257:1999;555-560.
69. O'Neil W.M., MacArthur R.D., Farrough M.J., Doll M.A., Fretland A.J., Hein D.W., Crane L.R., Svensson C.K. Acetylator phenotype and genotype in HIV-infected patients with and without sulfonamide hypersensitivity. J. Clin. Pharmacol. 42:2002;613-619.
70. Park B.K., Kitteringham N.R. Effects of fluorine substitution on drug metabolism: pharmacological and toxicological implications. Drug Metab. Rev. 26:1994;605-643.
71. Park B.K., Pirmohamed M., Kitteringham N.R. Role of drug disposition in drug hypersensitivity: a chemical, molecular and clinical perspective. Chem. Res. Toxicol. 9:1998;969-988.
72. Park B.K., Naisbitt D.J., Gordon S.F., Kitteringham N.R., Pirmohamed M. Metabolic activation in drug allergies. Toxicology. 158:2001;11-23.
73. Pichler W.J., Yawalkar N., Britschgi M., Depta J., Strasser I., Schmid S., Kuechler P., Naisbitt D. Cellular and molecular pathophysiology of cutaneous drug reactions. Am. J. Clin. Dermatol. 3:2002;229-238.
74. Pirmohamed M., Park B.K. HIV and drug allergy. Curr. Opin. Allergy Clin. Immunol. 1:2001;311-316.
75. Pirmohamed M., Alfirevic A., Vilar J., Stalford A., Wilkins E.G., Sim E., Park B.K. Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity. Pharmacogenetics. 10:2000;705-713.
76. Reilly T.P., Lash L.H., Doll M.A., Hein D.W., Woster P.M., Svensson C.K. A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J. Invest. Dermatol. 114:2000;1164-1173.
77. Robert J. Evolution of heat shock protein and immunity. Dev. Comp. Immunol. 27:2003;449-464.
78. Sachs B., Ronnau A.C., von Schmiedeberg S., Ruzicka T., Gleichmann E., Schuppe H.C. Lamotrigine-induced Stevens Johnson syndrome: demonstration of specific lymphocyte reactivity in vitro. Dermatology. 195:1997;60-64.
79. Schmid S., Kuechler P.C., Britschgi M., Steiner U.C., Yawalkar N., Limat A., Baltensperger K., Braathen L., Pichler W.J. Acute generalised exanthematous pustulosis: role of cytotoxic T cells in pustule formation. Am. J. Pathol. 161:2002;2079-2086.
80. Schnyder B., Mauri-Hellweg D., Zanni M., Bettens F., Pichler W.J. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. J. Clin. Invest. 100:1997;136-141.
81. Schnyder B., Frutig K., Mauri-Hellweg D., Limat A., Yawalkar N., Pichler W.J. T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazole- induced skin reaction. Clin. Exp. Allergy. 28:1998;1412-1417.
82. Schnyder B., Burkhart C., Schnyder-Frutig K., von Greyerz S., Naisbitt D.J., Pirmohamed M., Park B.K., Pichler W.J. Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. J. Immunol. 164:2000;6647-6654.
83. Sebastiani S., Allavena P., Albanesi C., Nasorri F., Bianchi G., Traidl C., Sozzani S., Girolomoni G., Cavani A. Chemokine receptor expression and function in CD4+ T lymphocytes with regulatory activity. J. Immunol. 166:2001;996-1002.
84. Sebastiani S., Albanesi C., De P.O., Puddu P., Cavani A., Girolomoni G. The role of chemokines in allergic contact dermatitis. Arch. Dermatol. Res. 293:2002;552-559.
85. Sharma V.K., Vatve M., Sawhney I.M., Kumar B. Clinical spectrum of drug rashes due to antiepileptics. J. Assoc. Phys. India. 46:1998;595-597.
86. Shi Y., Zheng W., Rock K.L. Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc. Natl. Acad. Sci. U.S.A. 97:2000;14590-14595.
87. Sidoroff A., Halevy S., Bavinck J.N., Vaillant L., Roujeau J.C. Acute generalised exanthematous pustulosis (AGEP) - a clinical reaction pattern. J. Cutan. Pathol. 28:2001;113-119.
88. Soler D., Humphreys T.L., Spinola S.M., Campbell J.J. CCR4 versus CCR10 in human cutaneous TH lymphocyte trafficking. Blood. 101:2003;1677-1682.
89. Summan M., Cribb A.E. Novel non-labile covalent binding of sulfamethoxazole reactive metabolites to cultured human lymphoid cells. Chem. Biol. Interact. 142:2002;155-173.
90. Suzuki Y., Inagi R., Aono T., Yamanishi K., Shiohara T. Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome. Arch. Dermatol. 134:1998;1108-1112.
91. Troger U., Brandt W., Rose W. Development of a pulmonary phenytoin-associated hypersensitivity reaction despite concomitant dexamethasone and prednisolone administration. Int. J. Clin. Pharmacol. Ther. 38:2000;452-456.
92. Uetrecht J.P. Reactivity and possible significance of hydroxylamine and nitroso metabolites of procainamide. J. Pharmacol. Exp. Ther. 232:1985;420-425.
93. Uetrecht J.P. New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system. Chem. Res. Toxicol. 12:1999;387-395.
94. Vance R.E. Cutting edge: cutting edge commentary: a Copernican revolution? Doubts about the danger theory. J. Immunol. 165:2000;1725-1728.
95. Walmsley S.L., Winn L.M., Harrison M.L., Uetrecht J.P., Wells P.G. Oxidative stress and thiol depletion in plasma and peripheral blood lymphocytes from HIV-infected patients: toxicological and pathological implications. AIDS. 11:1997;1689-1697.
96. Walsh J.S., Reese M.J., Thurmond L.M. The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes. Chem. Biol. Interact. 142:2002;135-154.
97. Williams D.P., Kitteringham N.R., Naisbitt D.J., Pirmohamed M., Smith D.A., Park B.K. Are chemically reactive metabolites responsible for adverse reactions to drugs? Curr. Drug Metab. 3:2002;351-366.
98. Wulferink M., Gonzalez J., Goebel C., Gleichmann E. T cells ignore aniline, a prohapten, but respond to its reactive metabolites generated by phagocytes: possible implications for the pathogenesis of toxic oil syndrome. Chem. Res. Toxicol. 14:2001;389-397.
99. Yawalkar N., Hari Y., Frutig K., Egli F., Wendland T., Braathen L.R., Pichler W.J. T cells isolated from positive epicutaneous test reactions to amoxicillin and ceftriaxone are drug specific and cytotoxic. J. Invest. Dermatol. 115:2000a;647-652.
100. Yawalkar N., Shrikhande M., Hari Y., Nievergelt H., Braathen L.R., Pichler W.J. Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. J. Allergy Clin. Immunol. 106:2000b;1171-1176.
101. Zakrzewska J.M., Ivanyi L. In vitro lymphocyte proliferation by carbamazepine, carbamazepine-10,11-epoxide, and oxcarbazepine in the diagnosis of drug-induced hypersensitivity. J. Allergy Clin. Immunol. 82:1988;110-115.
102. Zanni M.P., Mauri-Hellweg D., Brander C., Wendland T., Schnyder B., Frei E., von Greyerz S., Bircher A., Pichler W.J. Characterisation of lidocaine-specific T cells. J. Immunol. 158:1997;1139-1148.
103. Zanni M.P., von Greyerz S., Schnyder B., Brander K.A., Frutig K., Hari Y., Valitutti S., Pichler W.J. HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J. Clin. Invest. 102:1998;1591-1598.
104. Zhang L., Tinkle S.S. Chemical activation of innate and specific immunity in contact dermatitis. J. Invest. Dermatol. 115:2000;168-176.
105. Zinkernagel R.M. Localization dose and time of antigens determine immune reactivity. Semin. Immunol. 12:2000;163-171. (discussion 257-344).